Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New oral drug could stop blood cancer before it starts

NCT ID NCT07435636

First seen Mar 05, 2026 · Last updated May 24, 2026 · Updated 13 times

Summary

This study tests a low-dose oral drug (decitabine plus tetrahydrouridine) in 80 adults aged 60-85 with a high-risk blood condition called CCUS, which often leads to blood cancer. The drug aims to reduce harmful blood cell mutations and restore normal blood cell production without the harsh side effects of standard cancer treatments. Participants will receive either the drug or a placebo for 24 weeks to see if it can safely prevent disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Canberra Health Services

    Canberra, Australian Capital Territory, 2605, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Prince of Wales Hospital

    Randwick, New South Wales, 2031, Australia

    Contact Phone: •••-•••-••••

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.